Company
Zelira Therapeutics Ltd
OTCMKTS: ZLDAF
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is focused on the research, development and commercialisation of clinically validated cannabinoid based medicines. The company owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development.
62 stories
Zelira Therapeutics to streamline pipeline by acquiring pharmaceutical distributor Health House
The company is confident that the merger will be beneficial to both entities, improving margins for the total product output and providing stronger control of the product life cycle.
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
Zelira recently expanded into New Zealand via a 5-year exclusive distribution agreement with NUBU Pharmaceuticals, New Zealand’s largest medicinal cannabis distribution company.
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
The funds received will be used to support Zelira’s portfolio of products recently launched in global markets and to advance its ongoing clinical development programs.
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
The partial receipt of the upfront, non-refundable, non-contingent fee strengthens Zelira’s cash position, allowing it to continue to accelerate its prescription and OTC businesses and commercialisation strategies.
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
Publication of the trial in Pain And Therapy journal is testament to Zelira’s commitment to work with world-class researchers undertaking research that is critical to the continued maturation of the medicinal cannabis industry as a pharmace
Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market
The company has signed an exclusive distribution agreement with NUBU Pharmaceuticals to market Zenivol® and HOPE™1 in New Zealand.
Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid
The company can now proceed to the next phase of a clinical trial to test a cannabinoid treatment for sports injury pain.
Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal
“We have now demonstrated that Zelira’s proprietary Enhanced Distillate Capture and Dissolution Matrix technology substantially traps the distillate in a free flow powder matrix and increases the rate of dissolution,” says CEO.
Zelira Therapeutics research-backed products behind its impressive growth
“Our company continues to grow revenues with another record for quarterly cash receipts and 16% growth on the previous quarter,” CEO and managing director, Dr Oludare Odumosu said.
Kogan helps lift ASX … and Bitcoin goes into record breaking mode
“The turnaround for BTC has seen it close in on its previous all-time high - $63,569 - set on April 14 this year. Investors will now be watching closely to see if momentum is sustained to tip over that threshold." - Simon Peters
Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise
“The funds raised have not only introduced a new US-based fund onto Zelira’s register but more importantly, provides us with the capital to more aggressively roll out our growth strategy with a target of reaching financial breakeven by the
Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products
In FY21, the global medicinal cannabis company focused on expanding commercialisation activities and revenue generation from new clinically validated products.
Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products
“We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs," says CEO &
Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement
“Today is a landmark day for Zelira, with the expansion into Germany being a key growth milestone ... we are delighted to be partnering with Adjupharm, given their reputation for delivering high-quality products to pharmacies and pharmaceut
Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22
Commercialisation plans are focused on generating revenues from the multiple products it has launched into the Australian and US markets while expanding into new geographies such as the UK and Germany.
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
The cannabinoid medicines developer brought in more than A$300,000 from customers over FY21’s final quarter, marking the best quarterly result on record.
Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial
The medicines developer has locked down a key approval to test its own offering against a multi-billion-dollar drug in a 12-week observational study into neuropathic pain.
Zelira Therapeutics has clinical trial results of Zenivol® published in SLEEP®
Publishing the results in the prestigious peer-reviewed journal will provide prescribers with a higher level of confidence in using Zenivol to treat patients battling chronic insomnia.
Zelira Therapeutics research demonstrates significant uptake of CBD into the brain
Researchers have developed oral capsules containing cannabidiol (CBD) that penetrated the brain faster in mice models of neurological disease.
Zelira Therapeutics partners with Health House International to bring CBD toothpaste to the UK
Zelira’s CBD toothpaste is already available in the US. Now, the company is preparing to launch the product in another key large overseas market.
Zelira Therapeutics teams up with Levin Health to trial cannabinoid treatment for chronic pain in retired athletes
The licensing agreement will expand Zelira’s interest in chronic pain treatments while it continues to develop its insomnia and autism spectrum disorder candidates.
Zelira Therapeutics launches HOPE™ range of autism spectrum disorder products in Washington DC
The company is hopeful that through the partnership with Alternative Solutions LLC in Washington DC, which has reciprocity with 32 other US states, it can expand access for the HOPE™ range.
Zelira Therapeutics well-placed to build on considerable March quarter momentum
Other global markets with large populations, capacity to pay and legal at a national level are also a core focus, and include Germany and the UK.
Zelira Therapeutics delivers record March quarter revenue of $225,000
With a suite of new products planned for launch over the next two quarters, the company is well placed to generate further growth in revenue via diversified income streams.
Zelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sector
It is focused on developing branded cannabis products for a variety of medical conditions and is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid
Zelira Therapeutics positions for future growth with transition to US-based leadership team led by Dr Oludare Odumosu
Dr Richard Hopkins has decided to step down as chief executive officer and managing director ex-USA effective May 15, 2021.
Zelira Therapeutics appointed to the board of US National Cannabis Roundtable
The company will be represented on the NCR board by its US chief executive officer Oludare Odumosu.
Zelira Therapeutics in exclusive licensing deal with Alternative Solutions for distribution of HOPE™ products in Washington DC
Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from HOPE™ product sales in Washington DC.
Zelira Therapeutics cash balance boosted by $1.378 million R&D tax refund
The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.
Zelira Therapeutics partners with SprinJene to launch first over-the-counter CBD toothpaste in the US
Discussions are ongoing to access SprinJene’s global distribution networks in France, Russia, the UK, Singapore, Ukraine, China, Morocco, UAE, Saudi Arabia and Sudan Shoprite.
Zelira Therapeutics partners with Emyria for autism observational trial for HOPE products
The observational trial will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with ASD.
Zelira Therapeutics launches HOPE™ autism products in Australia through TGA Special Access Scheme
The products consist of two pharmaceutical-grade proprietary formulations developed to target Autism Spectrum Disorder as a disease indication.
Zelira Therapeutics secures $2 million strategic investment and new substantial shareholder
The Thorney Investment Group has increased its existing holding to become a substantial shareholder in Zelira Therapeutics rising to a 5.2% stake.
Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme
The cannabinoid medicine is supported by clinical trial data in patients with chronic insomnia and will now be available for prescription to patients in Australia through the Therapeutic Goods Administration Special Access Scheme.
Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA
Zelira has formed a new oral-healthcare subsidiary to commercialise a new line of hemp-derived cannabinoid-based oral care products.
Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers
The company’s HOPE 1 & 2 products are now available for sale in the US state, which has a population of more than 4.6 million.
Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation
Dr Richard Hopkins purchased 1 million shares in the heavily oversubscribed A$8.75 million placement and now holds 1.7 million shares.
Zelira Therapeutics set to roll-out products in more US states using licensing model
The company has successfully launched licensing deals in different jurisdictions, undertaking seven deals, including two in the US, in the first seven months of this year.
Zelira Therapeutics to outline progress of Zenivol™ and HOPE™ at Proactive's medical cannabis webinar on Aug 11
The developer of clinically validated cannabinoid-derived medicines, is reaching a major milestone as it accelerates its transition from a purely research-based organisation to become a revenue-generating company.
Three medical cannabis companies in focus at Proactive’s webinar on August 11
The select group of companies will join Proactive’s John Phillips at the virtual investor conference on Tuesday, August 11 at 12pm AEST (10am AWST).
Zelira Therapeutics accelerates transition to revenue-generation with Zenivol™ and HOPE™ launch in Australia by quarter-end
Zelira is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.
Zelira Therapeutics raises A$8.75 million to accelerate launch of products into global markets
The placement was strongly supported by new and existing sophisticated investors in Australia and the US and facilitated the entry of several new institutions from Australia onto the share register.
Zelira Therapeutics in trading halt ahead of capital raising news
Zelira is set to produce products based on CBD and other cannabinoids derived from hemp under an agreement with US-based Cardiovascular Solutions of Central Mississippi.
Zelira Therapeutics enters commercial agreement to develop products for vascular diseases
The licence granted by Zelira to CVSCM for the USA market with regard to the commercialisation of products developed under this agreement is for five years.
Zelira Therapeutics halted ahead of a licensing agreement in the United States
The global therapeutic medicinal cannabis company owns a portfolio of proprietary products positioned to enter global markets from 2020.
Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
The trial showed ZTL-103 is safe, with no serious adverse events reported, non-serious adverse events were mild and the maximal dose was generally well tolerated.
Zelira Therapeutics forming new partnership for chronic pain study in retired athletes
The chronic pain clinical trial is aimed at the large market for chronic pain treatment in retired athletes where medical cannabis may provide a safe and effective treatment.
Zelira Therapeutics finalises appointment terms of US CEO and managing director
Dr Odumosu’s background in biochemistry and healthcare entrepreneurship gives him unique qualifications to lead the US branch of Zelira Therapeutics.
Zelira Therapeutics signs commercial agreement for supply of Insomnia and HOPE products
The agreement with Tasmanian Alkaloids is for the exclusive manufacture of Zelira’s Insomnia and HOPE™ products in the Asia Pacific region.
Zelira Therapeutics in discussions to license medicinal cannabis products in US
The company released interim results of an Insomnia Clinical Trial during the quarter, the first in the world to have a primary endpoint assessing the impact of a full-spectrum cannabis extract on sleep.
Zelira Therapeutics shares surge after clinically validating medicinal cannabis for insomnia
Insomnia is a large unmet medical need. It affects ~30% of the US population and is a major risk factor for patients suffering chronic pain and neurological disorders.
Zelira Therapeutics accelerates towards commercialisation in 2020
The global therapeutic medicinal cannabis company owns a portfolio of proprietary products positioned to enter global markets from 2020.
Emerald Clinics gets nod for Zelira's opioid sparing clinical trial
The company is establishing and operating a network of clinics specialising in the creation of fit for purpose evidence.
Zelira Therapeutics fully enrols cannabis clinical trial
The clinical trial is dosing patients that have chronic non-cancer pain on long-term opioid pain relief.
Zelira Therapeutics achieves primary endpoints of medicinal cannabis trial for insomnia
Zelira is now poised to commercialise the world’s first clinically validated cannabis medicine for insomnia into global markets in 2020, including the US, based on the positive results of this study.
Zelira Therapeutics in trading halt ahead of insomnia trial results
The insomnia trial is designed to evaluate the safety and efficacy of a THC and CBD cannabinoid extract.
Zelira Therapeutics overseas interest boosts capital raising
Oversubscriptions from overseas investors boost the amount raised in the placement to total $4.64 million.
Zelira Therapeutics raises $4.59 million to accelerate product launches and clinical programs
The funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in 2020 and to advance its clinical programs.
Zelira Therapeutics halted with capital raising announcement pending
The halt will remain in place until the start of ASX trading on Wednesday, February 5 or when an announcement is released.
Zelira Therapeutics and US Parkinson’s Foundation collaborate for medicinal cannabis survey
The collaboration combines the foundation’s understanding of the underlying science of Parkinson’s disease and prevalent symptoms impacting people with the disease with Zelira’s extensive experience in medical cannabis product development.
Zelira Therapeutics completes dosing last patient in medicinal cannabis trial for insomnia
The trial is evaluating the safety and efficacy of a cannabinoid extract containing THC and CBD in patients with symptoms of clinically diagnosed chronic insomnia.